Phase II evaluation of adriamycin in human neoplasia.
D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D005069:Evaluation Studies as Topic; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006329:Heart Conduction System / Q000187:drug effects; D006333:Heart Failure / Q000139:chemically induced; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000188:drug therapy
D004317:Doxorubicin